Entity

Time filter

Source Type

Nagoya-shi, Japan

Patent
Kowa Company | Date: 2015-06-16

The present invention relates to hypotriglyceridemic agent containing HMG-CoA reductase inhibitor and cAMP protease inhibitor.


Patent
Kowa Company | Date: 2015-02-23

A hand joint supporter which can reduce the load on hand joints includes a first anchor section for tightening the wearers forearm with a tubular knitted fabric, a second anchor section for tightening the palm and back of the wearers hand with the fabric and a hole anchor section formed as a roughly circular through-hole in the vicinity of the second anchor section. A supporting section extends lengthwise in the fabric across the part covering the caprometacarpal joint and is joined to the first anchor section and the hole anchor section so as to support the wearers hand joints. Stretch resistance, in the circumferential direction of the fabric of the first anchor part is larger than that of a base fabric section, and stretch resistance, in the length width direction of the fabric, of the supporting section is larger than that of the base fabric section.


Patent
Kowa Company and UMEKEN Co. | Date: 2014-05-20

Provided is a granular product that has reduced or suppressed bitterness even though comprising a bitter crude drug or an extract thereof, and that allows a pharmacological action of the bitter crude drug to be sufficiently expressed. The granular product comprises a bitter crude drug or an extract thereof in each of the inner part and outer layer of the granular product.


Patent
Umeken Co. and Kowa Company | Date: 2014-05-22

A solid composition which contains a large amount of catechins and has solved problems concerning quality and producibility for exerting useful action and effects derived from catechins. The solid composition contains catechins and glycerol.


The present invention is intended to provide a pharmaceutical product for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the present invention is also intended to provide a preventive and/or therapeutic agent for various diseases based on inhibition of expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and the present invention relates to an agent for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and relates also to a preventive and/or therapeutic agent for various diseases based on the inhibition of the expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the agent comprising a compound represented by Formula (I), its salt, or a solvate of any of them as an active ingredient: wherein the symbols are the same as those given in the description.

Discover hidden collaborations